 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...4445464748495051525354...143144» |
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Reimbursement, Journal, HEOR, Medicare: Comparative Effectiveness of Biologic Agents Among Black and White Medicare Patients in the US With Metastatic Colorectal Cancer. (Pubmed Central) - Jan 12, 2022
In this comparative effectiveness analysis of a cohort of Medicare recipients with mCRC, biochemotherapy was associated with an improvement in OS with a similar rate of reduction in mortality among Black and White patients. Clinicians may offer biochemotherapy therapy to all patients to maximize clinical benefit, factoring in clinical variables, but not their race.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: The Tumour Suppressor CYLD Is Required for Clathrin-Mediated Endocytosis of EGFR and Cetuximab-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma. (Pubmed Central) - Jan 12, 2022
Regulation of EGFR trafficking by CYLD is thus critical for the antitumour activity of CTX. Our findings suggest the usefulness of a combination of cholesterol-lowering drugs with anti-EGFR antibody therapy in HNSCC.
- | New trial: MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer (clinicaltrials.gov) - Jan 11, 2022
P=N/A, N=250, Not yet recruiting, Sponsor: Xilis, Inc.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Genomic analysis of germline variation associated with survival of colorectal cancer patients treated with chemotherapy plus biologics in CALGB/SWOG 80405 (Alliance). (Pubmed Central) - Jan 11, 2022
A common SNP in AXIN1 confers worse OS and the effect is replicated in TCGA. Further studies in CRC experimental models are required.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Clinical, Journal: Expanded low allele frequency RAS and BRAF V600E testing in metastatic colorectal cancer as predictive biomarkers for cetuximab in the randomized CO.17 trial. (Pubmed Central) - Jan 11, 2022
Further studies in CRC experimental models are required. We establish single-agent cetuximab efficacy in optimally selected patients and show that subclonal RAS/BRAF alterations are uncommon and remain of indeterminate significance.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Terminal α2,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells. (Pubmed Central) - Jan 11, 2022
We establish single-agent cetuximab efficacy in optimally selected patients and show that subclonal RAS/BRAF alterations are uncommon and remain of indeterminate significance. Our data indicate that EGFR ⍺2,6-sialylation is a key factor in modulating the susceptibility of CRC cells to antibody targeted therapy, thereby disclosing a potential novel biomarker and providing key molecular information for tailor made anti-cancer strategies.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance. (Pubmed Central) - Jan 11, 2022
Next‑generation sequencing revealed that the frequency of inactivating mutations in NF1 were rare (1.8%) in patients with colorectal cancer and were not associated with the protein expression levels of NF1 except for in a small number of cases (0.5%), where the biallelic inactivation of NF1 was observed. To conclude, the present study showed that modification of NF1 expression can affect sensitivity to cetuximab in colorectal cancer cell lines, though a limitation exists in terms of its potential application as a biomarker for RAS and BRAF wild‑type tumors.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Review, Journal: Alpha-Gal Syndrome in Children: Peculiarities of a "Tick-Borne" Allergic Disease. (Pubmed Central) - Jan 11, 2022
We analyze the correlation between tick bites and symptom onset and unfold the different clinical pictures to help clinicians to promptly recognized this syndrome. Lastly, we address unmet needs in this specific allergy.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Review, Journal: Progress of molecular targeted therapy for head and neck cancer in clinical aspects. (Pubmed Central) - Jan 11, 2022
With the goal of improving local control, molecular targeted treatment strategies as salvage local therapy are being investigated, including boron neutron capture therapy (BNCT) and near-infrared photoimmunotherapy (NIR-PIT). Herein the history and landscape of molecular targeted therapy for head and neck cancers are summarized and reviewed.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Observational data, Retrospective data, Journal, Real-world evidence: Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study. (Pubmed Central) - Jan 8, 2022
Results demonstrated the long-term effectiveness of nivolumab and potential effectiveness of subsequent chemotherapy in patients with R/M HNC in the real-world setting. Safety was consistent with that over the 1-year follow-up.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Combination therapy: Cetuximab and paclitaxel combination therapy for recurrent basaloid squamous cell carcinoma in the ethmoid sinus. (Pubmed Central) - Jan 5, 2022
Combination therapy with weekly paclitaxel and cetuximab was started, and complete response was observed 2 months from treatment initiation. The patient has maintained complete response for 32 months, and no tumor regrowth has been observed.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Functional and mutational analysis after radiation and cetuximab treatment on prostate carcinoma cell line DU145. (Pubmed Central) - Jan 5, 2022
Cetuximab treatment did not induce resistance-mutations. Further research must clarify which combination of anti-EGFR treatment strategies can increase radiation-sensitizing-effects.
- | Enrollment open, Checkpoint inhibition, IO biomarker, Metastases: ECOG-ACRIN EA3202: Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (clinicaltrials.gov) - Jan 4, 2022
P2/3, N=216, Recruiting, Sponsor: National Cancer Institute (NCI)
Further research must clarify which combination of anti-EGFR treatment strategies can increase radiation-sensitizing-effects. Not yet recruiting --> Recruiting
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Genetic predictors of severe skin toxicity in stage III colon cancer patients treated with cetuximab: NCCTG N0147 (Alliance). (Pubmed Central) - Jan 4, 2022
Not yet recruiting --> Recruiting Retinoids have shown promise in the treatment of cetuximab-induced skin toxicity, so follow-up work could evaluate whether individuals with the RARA variant would benefit from retinoid therapy.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Evolving multidisciplinary treatment of squamous cell carcinoma of the head and neck in India. (Pubmed Central) - Jan 4, 2022
At progression, platinum-based CT combined with cetuximab (a monoclonal anti-epidermal growth factor receptor antibody) is the only validated option available as the first-line therapy. Thus, an integrated multidisciplinary approach plays a key role in maximizing patient outcomes, reduction in treatment related morbidities that consequently impact quality of life of survivors.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Distinct stratification of normal liver, Hepatocellular carcinoma (HCC), and anticancer nanomedicine treatment in tumour tissues by Raman fingerprinting for HCC therapeutic monitoring. (Pubmed Central) - Jan 4, 2022
HCC tumor and healthy liver tissues could be stratified. Raman spectroscopy served as an excellent, rapid, sensitive and cost-effective approach for anticancer nanomedicine distinct stratification of MTVDA encapsulated targeted cetuximab polymeric nanocomplex combinatorials, a significant potential for HCC therapeutic monitoring.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas. (Pubmed Central) - Jan 4, 2022
Interestingly, the cetuximab-resistant R521K tumors were successfully treated with c-MET tyrosine kinase inhibitor SU11274. Our results suggest that HNSCC cell line expressing the R521K mutant form of EGFR does not respond well to cetuximab treatment in vitro or in vivo, but hopefully might be targeted by c-MET tyrosine kinase inhibitor treatment.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck. (Pubmed Central) - Jan 4, 2022
Our results suggest that HNSCC cell line expressing the R521K mutant form of EGFR does not respond well to cetuximab treatment in vitro or in vivo, but hopefully might be targeted by c-MET tyrosine kinase inhibitor treatment. Cetuximab-induced rash is associated with better ORR and longer PFS and OS in patients with recurrent/metastatic HNSCC treated with Cetuximab and platinum-based chemotherapy.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Digitoxin promotes apoptosis and inhibits proliferation and migration by reducing HIF-1α and STAT3 in KRAS mutant human colon cancer cells. (Pubmed Central) - Jan 4, 2022
We also found that digitoxin administration inhibited tumor growth in a mouse xenograft model. Taken together, our findings highlight the therapeutic potential of digitoxin for the treatment of cetuximab-resistant human colon cancer.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: LncRNA UCA1 mediates Cetuximab resistance in Colorectal Cancer via the MiR-495 and HGF/c-MET Pathways. (Pubmed Central) - Jan 4, 2022
We provide the first evidence of a UCA1-miR-495-HGF/c-MET regulatory network involved in cetuximab resistance in CRC. Therefore, UCA1 has potential as a predictor and therapeutic target for cetuximab resistance.
- ||||||| Opdivo (nivolumab) / BMS
Trial completion, Trial completion date, Metastases: Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) (clinicaltrials.gov) - Jan 4, 2022
P3, N=506, Completed, Sponsor: Bristol-Myers Squibb
Therefore, UCA1 has potential as a predictor and therapeutic target for cetuximab resistance. Active, not recruiting --> Completed | Trial completion date: Oct 2020 --> Sep 2021
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Trial completion, Surgery: SULTAN: Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network (clinicaltrials.gov) - Jan 4, 2022
P2, N=20, Completed, Sponsor: UNICANCER
Active, not recruiting --> Completed | Trial completion date: Oct 2020 --> Sep 2021 Suspended --> Completed
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses. (Pubmed Central) - Jan 1, 2022
The oncologic outcomes in this cohort with locally advanced (mostly T4) disease are better than those historically reported in the literature. Further study of induction chemotherapy in patients with advanced sinonasal squamous carcinoma is warranted.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Retrospective data, Journal, Real-world evidence: Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study. (Pubmed Central) - Jan 1, 2022
The present study demonstrates that the combination of cetuximab with platinum-based CT was effective in R/M HNSCC. Among patients with R/M HSCC treated with platinum plus cetuximab as first-line therapy, primary site, ECOG-PS, grade 2-4 cetuximab induced toxicity, and weekly cetuximab monotherapy have a marked impact on OS.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: EGFR-targeted prodrug activation using bioorthogonal alkene-azide click-and-release chemistry. (Pubmed Central) - Jan 1, 2022
In a non-EGFR expressing melanoma cell line, no significant prodrug activation was observed. In vivo experiments using this combination of AB-d-TCO and the azido-doxorubicin prodrug in a murine melanoma model revealed no significant anti-tumour activity or increased survival, suggesting there was insufficient prodrug activation and drug release at the tumour site.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Repeated “Extreme” Liver Surgery in an Unresectable Patient: More than 10 Years of Follow-up (Rhinelander) - Dec 31, 2021 - Abstract #IHPBA2022IHPBA_443;
The patient came to our attention and received neoadjuvant therapy (10 cycles of FOLFIRI+cetuximab), then followed by a PSH consisting in a bisegmentectomy of S1-S4 with middle hepatic vein (MHV) preservation...Four cycles of “adjuvant” capecitabine were administered. In case of favorable tumor biology repeated “extreme” PSHs are feasible and positively affect the survival.
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, amiloride hydrochloride / Generic mfg., Vectibix (panitumumab) / Amgen, Takeda
Clinical: ☝🏽more success story; more on the #supportivecare #palliativecare front. Amiloride 2.5-5 mg 💊 For K+/Mg2+ wasting anti-#cancer agents. EGFR⛔️ Cetuximab Panitumumab Platinum agents etc. Just recommended to a patient on EGFR⛔️with K+ in the 2 & Mg2+ in low 1ish range. #CRCSM https://t.co/u8HQM9Vs4d (Twitter) - Dec 31, 2021
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
RETROSPECTIVE ANALYSIS ON THE ROLE OF BIOMOLECULAR MARKERS IN LOCO-REGIONALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMAS, TREATED WITH CHEMORADIOTHERAPY OR RADIOTHERAPY AND CETUXIMAB, PRECEDED OR NOT BY INDUCTION CHEMOTHERAPY ([VIRTUAL]) - Dec 31, 2021 - Abstract #AIOM2021AIOM_192;
HPV positivity and bcl-2 overexpression significantly correlated with PFS and OS in LAHNSCC. It is of interest the role of PD-L1 as, in its absence, immunotherapy loses most of its effectiveness while chemotherapy, in the context of PD-L1 negative cells, acquires the maximum ability to kill cancer cells.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
SKIN TOXICITY MANAGEMENT IN LEFT-SIDED RAS AND BRAF WILD-TYPE METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH FIRST-LINE ANTI-EGFR-BASED DOUBLET REGIMEN: A MULTICENTER STUDY ([VIRTUAL]) - Dec 31, 2021 - Abstract #AIOM2021AIOM_174;
Although recommended by international guidelines, a pre-emptive approach to the anti-EGFR-related skin toxicity in mCRC patients still appears less adopted in daily clinical practice compared to a reactive management. A wider reception and application of this indication is desirable to potentially improve quality of life of patients without impair continuity in antineoplastic therapy.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
MOLECULAR CORRELATES OF CLINICAL BENEFIT IN PREVIOUSLY TREATED PATIENTS (PTS) WITH BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER (MCRC) FROM THE BEACON STUDY ([VIRTUAL]) - Dec 31, 2021 - Abstract #AIOM2021AIOM_159;
Molecular characteristics and biological properties observed in BRAF V600E-mutant mCRC suggest that a subset of pts with specific molecular features may derive greater clinical benefit from triplet than doublet therapy. Additionally, these findings support the utility of gaining further understanding of the biological landscape in BRAF-mutant mCRC to enable potential hypotheses for pt selection to improve clinical outcome in future studies.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT BINIMETINIB IN BRAFV600E MUTATED (MUT) METASTATIC COLORECTAL CANCER (MCRC) PATIENTS: AN ITALIAN MULTICENTER REAL-LIFE EXPERIENCE (Topaz Room [VIRTUAL]) - Dec 31, 2021 - Abstract #AIOM2021AIOM_158;
The safety profile appears feasible with no unexpected AEs. A lower incidence of AEs is reported with the doublet, except for G1-2 skin toxicity.
- Hensify (crystalline hafnium oxide) / Nanobiotix, Erbitux (cetuximab) / Eli Lilly, EMD Serono
A phase I dose expansion study of NBTXR3, radiation enhancing hafnium oxide oparticles, for the treatment of cisplatinineligible locally advanced HNSCC patients ([VIRTUAL]) - Dec 31, 2021 - Abstract #SIOG2021SIOG_19;
Median age and tumor volume were 71.6 years and 60.6 mL respectively. ORR of the primary lesion was 82.5% and CRR was 62.5% (N = 40) at a median of 8.1 months after NBTXR3 injection.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal, Combination therapy: Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives. (Pubmed Central) - Dec 31, 2021
While the recommended dosing schedule for the triplet chemotherapy regimen with 5-fluorouracil, oxaliplatin and irinotecan (FOLFOXIRI) in combination with bevacizumab is well established, the optimal dosing of FOLFOXIRI in combination with anti-EGFR agents is unknown...Trials of anti-EGFR agents in combination with FOLFOXIRI have also shown promising results. In this review, we summarize the emerging evidence regarding the safety and efficacy of anti-EGFR agents in combination with triplet chemotherapy regimens and discuss the potential for this combination as a future treatment option for patients with RAS-wild-type mCRC.
- ||| NKTR-255 / Nektar Therap
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: Study of NKTR 255 in Combination With Cetuximab in Solid Tumors (clinicaltrials.gov) - Dec 30, 2021
P1b/2, N=326, Recruiting, Sponsor: Nektar Therapeutics
In this review, we summarize the emerging evidence regarding the safety and efficacy of anti-EGFR agents in combination with triplet chemotherapy regimens and discuss the potential for this combination as a future treatment option for patients with RAS-wild-type mCRC. N=78 --> 326 | Trial completion date: Apr 2023 --> Aug 2024 | Trial primary completion date: Apr 2022 --> Jun 2023
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: CA225200: PhII ICb With/Without Erbitux in MBC Pts (clinicaltrials.gov) - Dec 28, 2021
P2, N=154, Active, not recruiting, Sponsor: US Oncology Research
N=78 --> 326 | Trial completion date: Apr 2023 --> Aug 2024 | Trial primary completion date: Apr 2022 --> Jun 2023 Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: May 2014 --> Dec 2022
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME. (Pubmed Central) - Dec 28, 2021
Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: May 2014 --> Dec 2022 Although the continuation of cetuximab in combination with paclitaxel after EXTREME provides moderate benefit, it could be an interesting option for selected patients.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, BRCA Biomarker, IO biomarker: Longitudinal change of genetic variations in cetuximab-treated metastatic colorectal cancer. (Pubmed Central) - Dec 28, 2021
Collectively, we identified recurrent variations in mCRC samples exhibiting post-cetuximab progression. Additionally, future studies are required to evaluate the therapeutic potential of these variations.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies. (Pubmed Central) - Dec 28, 2021
However, further optimizations, aimed towards illuminating the multifaceted interplay, are required to avoid toxicity and to achieve better therapeutic effectiveness. The current review summarizes existing (pre-)clinical evidence to provide a rationale supporting the use of combined cetuximab and immunotherapy approaches in patients with different types of cancer.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Shooting at Moving and Hidden Targets-Tumour Cell Plasticity and the Notch Signalling Pathway in Head and Neck Squamous Cell Carcinomas. (Pubmed Central) - Dec 27, 2021
Only very recently, newer targeted therapies have entered the clinics, including Cetuximab, which targets the EGF receptor (EGFR), and several immune checkpoint inhibitors targeting the immune receptor PD-1 and its ligand PD-L1...Notch signalling also interacts with numerous other signalling pathways, that may also have a decisive impact on tumour cell plasticity, acquired radio/chemoresistance, and metastatic progression of HNSCC. We outline the current stage of research related to Notch signalling, and how this pathway may be intricately interconnected with other, druggable targets and signalling mechanisms in HNSCC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Depletion of METTL3 alters cellular and extracellular levels of miRNAs containing mA consensus sequences. (Pubmed Central) - Dec 24, 2021
Functional testing of EVs prepared from cells expressing shRNAs against METTL3 showed that they were less capable of conferring colony growth in 3D to wild-type KRAS cells and were also largely incapable of conferring the spread of cetuximab resistance. Our data support a role for METTL3 modification on cellular miRNA levels and export of specific miRNAs.
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical: First line FOLFOX cetuximab X3 course Progressive Disease (PD) - While taking cetuximab, the F1cDX(tissue) had not yet been reported. All RAS and MSı status were examined by PCR only and negative. (Twitter) - Dec 23, 2021
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Gefitinib combined with cetuximab for the treatment of lung adenocarcinoma harboring the EGFR-IGR (SEC61G) fusion and EGFR amplification. (Pubmed Central) - Dec 23, 2021
The EGFR-IGR fusion mutation is unreported, and thus, there are no studies targeting this fusion together with EGFR amplification in lung adenocarcinoma. Our brief study provides clinical evidence that combined targeted therapy with gefitinib and cetuximab could result in a significant antitumor response in patients with the EGFR-IGR fusion and EGFR amplification.
- | Ibrance (palbociclib) / Pfizer
Enrollment closed, Trial completion date, Trial primary completion date, Monotherapy: Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Dec 22, 2021
P2, N=26, Active, not recruiting, Sponsor: Washington University School of Medicine
Our brief study provides clinical evidence that combined targeted therapy with gefitinib and cetuximab could result in a significant antitumor response in patients with the EGFR-IGR fusion and EGFR amplification. Recruiting --> Active, not recruiting | Trial completion date: Jan 2028 --> Apr 2027 | Trial primary completion date: Oct 2022 --> Feb 2022
- |||| Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, evorpacept (ALX148) / ALX Oncology
New P2 trial, Combination therapy, Metastases: A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 22, 2021
P2, N=80, Not yet recruiting, Sponsor: Criterium, Inc.
- ||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P3 data, Journal, Adverse events: Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized phase III trial FIRE-3 (AIO KRK-0306). (Pubmed Central) - Dec 22, 2021
Patients exhibiting EWL had worse survival and higher frequencies of adverse events. Early preventative measures targeted at weight maintenance should be evaluated, especially in elderly patients being at highest risk of EWL.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes. (Pubmed Central) - Dec 21, 2021
P2
Early preventative measures targeted at weight maintenance should be evaluated, especially in elderly patients being at highest risk of EWL. Selection of patients with mCRC based on their KIR genotypes opens a therapeutic opportunity for patients with KRAS mutation, and it should be tested in clinical trials in comparison with other alternatives with scarce benefit.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone. (Pubmed Central) - Dec 21, 2021
The subtype-specific efficacy of anti-EGFR therapy is dependent on the chemotherapy backbone. This may provide the possibility of subtype-specific treatment strategies for a more optimal use of anti-EGFR therapy.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Milking the Cow: Cattle-Derived Chimeric Ultralong CDR-H3 Antibodies and Their Engineered CDR-H3-Only Knobbody Counterparts Targeting Epidermal Growth Factor Receptor Elicit Potent NK Cell-Mediated Cytotoxicity. (Pubmed Central) - Dec 21, 2021
Besides slightly to moderately diminished capacities, these engineered Knobbodies largely retained main properties of their parental antibodies such as cellular binding and triggering of ADCC. Hence, Knobbodies might emerge as promising tools for biotechnological applications upon further optimization.
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS, Vectibix (panitumumab) / Amgen, Takeda
Clinical: Was this paper peer-reviewed???? *$@# 🤬 - Mixing heme and solid tumors - Considering Panitumumab, Cetuximab and Nivolumab as "genomic indications" "Overall survival for oncology drugs approved for genomic indications" https://t.co/Q1txgVJgdx (Twitter) - Dec 20, 2021
- | Journal: Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer. (Pubmed Central) - Dec 20, 2021
Response and longer PFS to prior osimertinib may be predictive of response to afatinib. Strategies based on osimertinib resistance mechanisms may further define the role of subsequent afatinib.